In a preclinical immunoactive ovarian cancer mouse model, AAV gene therapy vectors were used to express 3TSR alone or in combination with the CD47-binding peptide of TSP-1 to assess its effect on tumor development and survival. The gene discussed is CD47; the disease is ovarian carcinoma.